NCT01715259 - A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Renal Insufficiency

Interventions

DRUG

Abiraterone acetate: participants with end-stage renal disease

abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1

DRUG

Abiraterone acetate: matched control participants with normal renal function

abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1

Trial Locations (1)

Orlando